Japanese encephalitis virus infection reshapes the gut microbiome and induces colonic inflammation in neonatal mice

ABSTRACT Japanese encephalitis virus (JEV), a neurotropic flavivirus, predominantly causes severe infection in children, leading to neuropsychiatric complications. Given that the juvenile period is a transitional window for the gut microbiota to develop into a stable community profile, any alterations to the microbiota during infections can result in chronic inflammation. Therefore, we investigated changes in the gut microbiota of neonatal mice during the early and late stages of JEV infection. Postnatal day 10, BALB/c mice challenged with JEV succumbed to acute infection at 6 to 7 days post-infection. This severity was marked by a surge in systemic pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, and MCP-1) and reduced food intake. Fecal 16S rRNA V3-V4 sequencing revealed distinct β-diversity between mock and JEV-infected groups, with the dominant phyla being Firmicutes, Bacteroidota, and Proteobacteria. The relative abundance of these phyla shifted, with Firmicutes decreasing from ~63.7% (control) to ~39% (JEV), whereas Proteobacteria remained unchanged in JEV. The Firmicutes/Bacteroidota ratio decreased in JEV, along with a reduction in Lactobacillus . Simultaneously, altered mucosal secretion, reduced tight-junction protein ZO-1, increased pNF-κB, and cleaved caspase-3 together indicated colonic inflammation. Prediction of microbial pathways using PICRUSt2 suggested a reduction in specific pathways associated with beneficial secondary metabolites and short-chain fatty acids (SCFAs) in JEV. Intragastric administration of the SCFA cocktail prolonged survival and delayed the onset of clinical signs and the inflammatory response. Our findings suggest that systemic inflammation and reduced feeding during an acute infection could result in colonic dysbiosis, reduced beneficial bacteria, and trigger inflammation. SCFAs displayed a transient therapeutic effect in JEV infection, highlighting the potential of gut microbiota modulation to manage acute viral infection. IMPORTANCE Japanese encephalitis remains a leading cause of viral encephalitis in children across the Asia-Pacific region, with new outbreaks driven by evolving demographic factors. The need for targeted therapies beyond existing supportive care underscores the need for new host-directed interventions. Our findings suggest that gut-brain axis interactions may play a role in acute viral infections, potentially amplifying disease severity through infection-driven reduction in feeding, increased cytokine production, and shifts in the gut microbiome. We propose that SCFA supplementation can serve as a microbiota-modulating strategy that offers a safe, translatable approach to managing inflammation and JEV outcomes in pediatric viral encephalitis. This could be utilized as a supplement along with supportive care in other flavivirus infections.

Authors

Institutions

Publication Details

Journal
mBio
Published
2026-11-16
DOI
https://doi.org/10.1128/mbio.02437-26
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Japanese encephalitis virus infection reshapes the gut microbiome and induces colonic inflammation in neonatal mice

Anirban Basu, Anirudh Satheesan, Akasmika Priyadarsani
3 links
mBio
Gut microbiota and health
article

Japanese encephalitis virus infection reshapes the gut microbiome and induces colonic inflammation in neonatal mice

Anirban Basu, Anirudh Satheesan, Akasmika Priyadarsani
article en

Abstract

ABSTRACT Japanese encephalitis virus (JEV), a neurotropic flavivirus, predominantly causes severe infection in children, leading to neuropsychiatric complications. Given that the juvenile period is a transitional window for the gut microbiota to develop into a stable community profile, any alterations to the microbiota during infections can result in chronic inflammation. Therefore, we investigated changes in the gut microbiota of neonatal mice during the early and late stages of JEV infection. Postnatal day 10, BALB/c mice challenged with JEV succumbed to acute infection at 6 to 7 days post-infection. This severity was marked by a surge in systemic pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, and MCP-1) and reduced food intake. Fecal 16S rRNA V3-V4 sequencing revealed distinct β-diversity between mock and JEV-infected groups, with the dominant phyla being Firmicutes, Bacteroidota, and Proteobacteria. The relative abundance of these phyla shifted, with Firmicutes decreasing from ~63.7% (control) to ~39% (JEV), whereas Proteobacteria remained unchanged in JEV. The Firmicutes/Bacteroidota ratio decreased in JEV, along with a reduction in Lactobacillus . Simultaneously, altered mucosal secretion, reduced tight-junction protein ZO-1, increased pNF-κB, and cleaved caspase-3 together indicated colonic inflammation. Prediction of microbial pathways using PICRUSt2 suggested a reduction in specific pathways associated with beneficial secondary metabolites and short-chain fatty acids (SCFAs) in JEV. Intragastric administration of the SCFA cocktail prolonged survival and delayed the onset of clinical signs and the inflammatory response. Our findings suggest that systemic inflammation and reduced feeding during an acute infection could result in colonic dysbiosis, reduced beneficial bacteria, and trigger inflammation. SCFAs displayed a transient therapeutic effect in JEV infection, highlighting the potential of gut microbiota modulation to manage acute viral infection. IMPORTANCE Japanese encephalitis remains a leading cause of viral encephalitis in children across the Asia-Pacific region, with new outbreaks driven by evolving demographic factors. The need for targeted therapies beyond existing supportive care underscores the need for new host-directed interventions. Our findings suggest that gut-brain axis interactions may play a role in acute viral infections, potentially amplifying disease severity through infection-driven reduction in feeding, increased cytokine production, and shifts in the gut microbiome. We propose that SCFA supplementation can serve as a microbiota-modulating strategy that offers a safe, translatable approach to managing inflammation and JEV outcomes in pediatric viral encephalitis. This could be utilized as a supplement along with supportive care in other flavivirus infections.

mBio
National Brain Research Centre (IN)
National Research Foundation, National Brain Research Centre
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon